Search for:
Author

Andy Leck

Browsing
Andy Leck is the managing principal of Baker McKenzie.Wong & Leow. Mr. Leck is recognised by the world’s leading industry and legal publications as a leader in his field. Asian Legal Business notes that he “always gives good, quick advice, [is] client-focused and has strong technical knowledge for his areas of practice”. Alongside his current role as managing principal, Mr. Leck has held several leadership positions in the Firm and externally as a leading IP practitioner. He currently serves on the International Trademark Association's Board of Directors and is a member of the Singapore Copyright Tribunal.

The Singapore High Court refused a consumer’s attempt to re-file a failed claim after the lower court issued a final and unappealable decision. The consumer first brought a claim against e-commerce platform Lazada at the Small Claims Tribunal. After a decision was made, the consumer applied to the District Court for leave to appeal against the decision. The District Court refused to grant leave to appeal, which, under law, is considered as final. However, the consumer still brought a claim before the High Court, arguing that she was filing a fresh claim in respect of the damages that were not granted. The claim was refused.

On 19 July 2021, the Medical Devices Branch (MDB) of the Health Sciences Authority (HSA) published its draft “Regulatory Guidelines on Risk Classification of Standalone Medical Mobile Applications (SaMD) and Qualification of Clinical Decision Support Software (CDSS)” for comments.

The Singapore Health Sciences Authority is trialing an e-commerce surveillance tool to crack down on contraband products sold online, including illegal drugs, health products and cosmetics. The bot uses robotic process automation and artificial intelligence to trawl through online listings. It analyses information from the listings, including pictures, descriptions and profiles, to identify illegal products and listings that contain illegal or dangerous ingredients.

On 19 July 2021, the Medical Devices Branch (MDB) of the Health Sciences Authority (HSA) published its draft “Regulatory Guidelines on Risk Classification of Standalone Medical Mobile Applications (SaMD) and Qualification of Clinical Decision Support Software (CDSS)” for comments.